(12) United States Patent (10) Patent No.: US 8,859,556 B2 Svensson Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) United States Patent (10) Patent No.: US 8,859,556 B2 Svensson Et Al US008859556B2 (12) United States Patent (10) Patent No.: US 8,859,556 B2 Svensson et al. (45) Date of Patent: Oct. 14, 2014 (54) TRPA1 RECEPTOR ANTAGONIST OTHER PUBLICATIONS (75) Inventors: Mats Svensson, Sodertalje (SE); Dirk Bandell et al., “Noxious Cold Ion Channel TRPAl Is Activated by Weigelt, Ronninge (SE) Pungent Compounds and Bradykinin’. Neuron 2004, 41(6), 849 857. (73) Assignee: Acturum Life Science AB, Solna (SE) Bautista et al. “TRPAl Mediates the Inflammatory Actions of Envi ronmental Irritants and Proalgesic Agents”. Cell 2006, 124(6), 1269 (*) Notice: Subject to any disclaimer, the term of this 1282. patent is extended or adjusted under 35 Jaquemar et al., “An Ankyrin-like Protein with Transmembrane U.S.C. 154(b) by 0 days. Domains Is Specifically Lost after Oncogenic Transformation of Human Fibroblasts”, J Biol Chem 1999, 274(11), 7325-7333. (21) Appl. No.: 13/878,862 Kremeyer et al. "A Gain-of-Function Mutation in TRPAl Causes Familial Episodic Pain Syndrome'. Neuron 2010, 66(5), 671-680. (22) PCT Filed: Oct. 11, 2011 Kwan et al., “TRPA1 Contributes to Cold, Mechanical, and Chemical Nociception but Is Not Essential for Hair-Cell Transduction”, Neu (86). PCT No.: PCT/SE2O11AOS1213 ron 2006, 50(2), 277-289. McGaraughty et al. “TRPA1 modulation of spontaneous and S371 (c)(1), mechanically evoked firing of spinal neurons in uninjured, (2), (4) Date: Jun. 19, 2013 osteoarthritic, and inflamed rats'. Molecular Pain 2010, 6:14. McNamara et al. “TRPA1 mediates formalin-induced pain'. Proc (87) PCT Pub. No.: WO2012/050512 Natl AcadSci USA 2007, 104(33), 13525-13530. PCT Pub. Date: Apr. 19, 2012 Primary Examiner — Kahsay Habte (65) Prior Publication Data (74) Attorney, Agent, or Firm — Baker & Hostetler LLP US 2014/0148466A1 May 29, 2014 (57) ABSTRACT Related U.S. Application Data A compound of Formula (I), pharmaceutically acceptable salts thereof, enantiomers, or mixtures thereof: pharmaceuti (60) Provisional application No. 61/392,130, filed on Oct. cal compositions containing said compounds, enantiomers or 12, 2010. mixtures; processes for making said compounds, enanti (51) Int. Cl. omers or mixtures; the use of said compounds, enantiomers or CO7D 40/4 (2006.01) mixtures; and medicaments containing the same for treatment C07D 213/74 (2006.01) of pain and other conditions; and methods of treating pain and A6 IK3I/44 (2006.01) other conditions with the same. (52) U.S. Cl. USPC ...................................... 514/253.01:544/360 (58) Field of Classification Search (I) USPC ...................................... 544/360; 514/253.01 See application file for complete search history. (56) References Cited U.S. PATENT DOCUMENTS 2009,0176883 A1 7/2009 Perner et al. 2009/0325987 A1 12/2009 Muthuppalniappan et al. FOREIGN PATENT DOCUMENTS WO WO2005/O12287 2, 2005 WO WO2OO7 O73505 6, 2007 WO WO2008/007103 1, 2008 WO WO2010/075353 T 2010 7 Claims, 2 Drawing Sheets U.S. Patent Oct. 14, 2014 Sheet 1 of 2 US 8,859,556 B2 Figure 1. Counts 1 OOO 500 10 20 30 Position (2Theta) U.S. Patent Oct. 14, 2014 Sheet 2 of 2 US 8,859,556 B2 Figure 2. AbS. 1) Experimental VCD spectrum of example 6 | -- /N ^\ r -\'v. \ ^- A -- - - - - -/A \- y V ;—-y 2) Inversion - Of calculated VCD?'--/--/ spectrum (4)N/--- . A.\J n \W. /N--------Y. --. /. : 3) Experimental VCD spectrum of example 7 i --- rt-:''- - ------ ,--- --- ---...-- i ''. 4) Calculated VCD Spe trum for fragment (II) y- -- - - -- W ---, r - \/\----, | Ay A- \- ill- v/ -- --- 1700 1600 1500 1400 1300 1200 1100 1000 900 Wavenumbers (cm) VCD Experimental and Calculated Spectra. US 8,859,556 B2 1. 2 TRPA1 RECEPTOR ANTAGONST pensity to work as an analgesic in vivo. An object of the present invention is therefore to provide new, improved and FIELD OF THE INVENTION useful analgesics. The present invention relates to antagonists of the transient SUMMARY OF THE INVENTION receptor potential (TRP) family of ion channels. The present Non-selective cation channel TRPA1 antagonists are invention also provides compositions comprising Such described. The described antagonists can be used for treating antagonists and methods therewith for treating diseases medi pain and other conditions. Medical conditions which are ated by the transient receptor potential (TRP) family of ion mediated by TRPA1 antagonists include asthma, pertussis channels. Particularly, the present invention is related to non 10 and nicotine addiction. selective cation channel TRPA1 antagonist compounds use ful for treating pain and other specific disorders. BRIEF DESCRIPTION OF THE DRAWINGS BACKGROUND FIG. 1 shows an X-Ray Powder Diffraction (XRPD) pat 15 tern for the compound of Example 6. The transient receptor potential (TRP) family of ion chan FIG. 2 shows VCD Spectra for compounds. nels are often found to be sensors of multiple chemical and physical stimuli (temperature, Smell, taste and noxious DETAILED DESCRIPTION OF THE INVENTION chemicals). Particularly, the non-selective cation channel TRPA1 (transient receptor potential ankyrin-repeat 1), origi The present invention thus provides new antagonists of the nally cloned as an ankyrin-like protein (Jaquemar et al 1999, non-selective cation channel TRPA1. The new antagonists J Biol Chem 274:7325-7333), is activated by multiple pun can be used for, amongst other things, treating pain. Further gent and pro-algesic compounds (Bandell et al 2004, Neuron medical conditions which are mediated by TRPA1 antago 41: 849-857). Recent reviews on TRPA1 as pharmaceutical nists include asthma, pertussis and nicotine addiction. target have been published by Rechet al. (Future Med. Chem. 25 In a first aspect, the present invention provides a compound 2010: 843-838) and by Baraldi et al (J. Med. Chem. 2010, of Formula (I), a pharmaceutically acceptable salt thereof, 5085-2107). TRPA1 is highly expressed in a subset of C-fiber enantiomer, or mixture thereof: nociceptors in the peripheral nerve system (Kobayashi et al (I) 2005, J. Comp Neurol 493(4):596-606). When activated TRPA1 permits the conduction ofcations (primarily Ca" and 30 2 Na") from the extra cellular environment into the cell, thereby depolarizing the membrane potential and affecting calcium homeostasis in the primary afferents. Depolarization primary nerve terminals lead to action potential firing and conse quently increased pain sensation and hyperalgesia in man and 35 rodent experimental models (Jiang and Gebhart 1998, Pain 77(3):305-13; Cervero and Laird 1996, Pain 68(1):13–23). The pungent ingredient in mustard oil: allyl isothiocyanate (AITC), concentration dependently activates TRPA1 in vitro measured both on sodium current and calcium influx. Further, 40 AITC also excites small diameter afferent fibers (Reeh 1986, It will be understood that as a compound of the present Brain Res 384:42-50) and indeed topical application of AITC invention contains one chiral centers, the compound may induces pain and hyperalgesia in man (Namer et al 2005, exist in, and be isolated as, enantiomeric forms, or as a race Neuroreport 16(9):955-959). Recently TRPA1 knock out mic mixture. The present invention includes any possible (KO) mice were described to have lost AITC sensitivity and 45 enantiomers, racemates or mixtures thereof, of a compound display severely impaired bradykinin pain response signal of Formula (I). The optically active forms of the compound of ling (Kwan 2006, Neuron 50(2):277-289; Bautista 2006, Cell the invention may be prepared, for example, by chiral chro 124(6):1269-1282). Formalin, which is a mixture of metha matographic separation of a racemate, by synthesis from opti nol, water and formaldehyde is a widely used rodent model cally active starting materials or by asymmetric synthesis for evaluating analgesic compounds in vivo. TRPA1 is acti 50 based on the procedures described thereafter. vated by formaldehyde in vitro and recently it was shown that One embodiment of the present invention is the (R) enan TRPA1 KO mice almost have their response to formalin/ tiomer of a compound of Formula (I) having the following formaldehyde abolished (McNamara et al 2007, Proc Natl Structure: AcadSci USA 104(33):13525-13530). A Hydra Biosciences proprietary compound (HCO30031) is a TRPA1 antagonist in 55 vitro and has been shown to alleviate the formalin induced 2 pain behaviour in a dose dependant way (McNamara 2007, Proc Natl Acad Sci USA 104(33):13525-13530 and WO2007/073505A2). An Abbott proprietary compound (US l 2009/0176883 and McGaraughty et al., Molecular Pain 2010 r^- 6:14) with in vitro effect on TRPA1 showed to have in vivo 60 N Nu O effect in a rat osteoarthritis pain model as well as a number of Glenmark proprietary compounds (US 2009/0325987) showed in several in vivo pain models. It has also been shown l that a mutation in TRPA1 causes FEPS (“Familial Episodic Pain Syndrome', Kremeyeretal, Neuron 2010, 66:671-680). 65 It is therefore suggested that in vitro inhibition of the TRPA1 It will also be understood that a compound of the present calcium and Sodium influx will determine a compound's pro invention may exist in Solvated, for example hydrated, as well US 8,859,556 B2 3 4 as unsolvated forms. It will further be understood that the tive pain, inflammatory pain, central pain, central and periph present invention encompasses all such solvated forms of the eral neuropathic pain, central and peripheral neurogenic pain, compound of the Formula (I). central and peripheral neuralgia, chronic tendinitis, low back Within the scope of the invention are also salts of the pain, postoperative pain, peripheral neuropathy, visceral compound of the Formula (I). Generally, pharmaceutically pain, pelvic pain, allodynia, anesthesia dolorosa, causalgia, acceptable salts of compound of the present invention may be dysesthesia, fibromyalgia, hyperalgesia, hyperesthesia, obtained using standard procedures well known in the art, for hyperpathia, ischemic pain, Sciatic pain, pain associated with example by reacting a sufficiently basic compound, for cystitis, including but not limited to interstitial cystitis, pain example an alkylamine with a suitable acid, for example, HCl associated with multiple Sclerosis, pain associated with or acetic acid, to afford a physiologically acceptable anion.
Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • United States Patent (19) (11) 4,213,981 Wetzel 45) Jul
    United States Patent (19) (11) 4,213,981 Wetzel 45) Jul. 22, 1980 (54) INJECTABLE ANESTHETIC (56) References Cited (75) Inventor: Jon C. Wetzel, Plattsburgh, N.Y. U.S. PATENT DOCUMENTS 3,330,826 7/1967 Schmitt et al. ....................... 424/247 73 Assignee: American Home Products 3,567,831 3/1971 Middleton et al. ...... ... 424/273 Corporation, New York, N.Y. OTHER PUBLICATIONS 21 Appl. No.: 941,999 Chemical Abstracts 75:47209p (1971). 22) Filed: Sep. 13, 1978 Primary Examiner-Jerome D. Goldberg (57) ABSTRACT Related U.S. Application Data A new anesthetic composition comprising a specified mixture of acepromazine or its pharmaceutically ac (63) Continuation-in-part of Ser. No. 787.643, Apr. 14, ceptable salts and midaflur is disclosed. This composi 1977, abandoned. tion induces a useful surgical plane of anesthesia in 2 r mammals while substantially reducing troublesome side 51 int. Cl." ...................... A6K 31/415, A61 K 31/54 effects encountered with the use of midaflur by itself. 52 U.S. Cl. ................................. 424/247; 424/273 R 58 Field of Search....................... 424/273 R, 424/247 7 Claims, No Drawings 4,213,981 1. 2 Surgical Plane-For all species with the exception of NJECTABLE ANESTHETIC horses, the surgical plane was defined as the time from injection until the last recorded time the pedal BACKGROUND OF THE INVENTION reflex was abolished or the animals showed no indica tion of a pain response (pigs and sheep only). In 1. Field of the Invention horses, the surgical plane was the time from injection This application is a continuation-in-part of Ser.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0152713 A1 Petrie (43) Pub
    US 2004O152713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0152713 A1 Petrie (43) Pub. Date: Aug. 5, 2004 (54) METHODS FORTREATING JOINT PAIN OR (52) U.S. Cl. ...................... 514/266.2, 514/310; 514/314; IMPROVING SLEEP USING AN ESTROGEN 514/256 AGONISTIANTAGONIST (57) ABSTRACT (75) Inventor: Charles D. Petrie, Cranston, RI (US) The present invention provides methods, pharmaceutical Correspondence Address: compositions and kits for treating joint pain and/or improv PFIZER INC. ing sleep using a SERM of formula (I): PATENT DEPARTMENT, MS8260-1611 EASTERN POINT ROAD GROTON, CT 06340 (US) (I) (73) Assignee: Pfizer Inc. (21) Appl. No.: 10/761,672 (22) Filed: Jan. 21, 2004 Related U.S. Application Data (60) Provisional application No. 60/441,830, filed on Jan. 22, 2003. Publication Classification wherein the variables A, B, D, E, e, G, Y and Z are as (51) Int. Cl.' .................... A61K 31/517; A61K 31/4709 defined in the Specification. US 2004/0152713 A1 Aug. 5, 2004 METHODS FOR TREATING JOINT PAIN OR ceSS is associated with changes to an individual's circadian IMPROVING SLEEP USING AN ESTROGEN and diurnal rhythms. With increasing age the total amount of AGONISTIANTAGONIST Sleep tends to shorten and the amount of deep sleep can decrease or disappear. Sleep may become more fragmented FIELD OF THE INVENTION and interrupted for the elderly and these changes with timing 0001. This invention relates to methods for treating joint and Structure of Sleep are often associated with Significant pain and/or improving sleep using an estrogen agonist/ morbidity. Similarly, non-elderly individuals may also antagonist also known as Selective estrogen receptor modu exhibit disturbances in the normal Sleep process.
    [Show full text]